{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T06:01:49Z","timestamp":1668492109044},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T00:00:00Z","timestamp":1515542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3,10]]},"DOI":"10.1093\/ajh\/hpy003","type":"journal-article","created":{"date-parts":[[2018,1,5]],"date-time":"2018-01-05T20:25:24Z","timestamp":1515183924000},"page":"405-406","source":"Crossref","is-referenced-by-count":0,"title":["Mineralocorticoid Receptor Antagonists Treatment in Resistant Hypertension and HFpEF: Evidence and Courage"],"prefix":"10.1093","volume":"31","author":[{"given":"Daniel","family":"Duprez","sequence":"first","affiliation":[{"name":"Cardiovascular Division, Department of Medicine, Medical School University of Minnesota, Minneapolis, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aigerim","family":"Toleuova","sequence":"additional","affiliation":[{"name":"Department of Research, Minneapolis VA Health Care System, Minneapolis, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,1,10]]},"reference":[{"key":"2022111419405462600_CIT0001","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jchf.2017.08.011","article-title":"Refining classification of heart failure based on ejection fraction","volume":"5","author":"Fonarow","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2022111419405462600_CIT0002","article-title":"An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology","author":"Louren\u00e7o","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2022111419405462600_CIT0003","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.amjmed.2016.01.039","article-title":"Resistant hypertension and the pivotal role for mineralocorticoid receptor antagonists: a clinical update 2016","volume":"129","author":"Epstein","year":"2016","journal-title":"Am J Med"},{"key":"2022111419405462600_CIT0004","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/ajh\/hpu151","article-title":"Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations","volume":"28","author":"Achelrod","year":"2015","journal-title":"Am J Hypertens"},{"key":"2022111419405462600_CIT0005","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/ajh\/hpw105","article-title":"Use of aldosterone antagonists for treatment of uncontrolled resistant hypertension","volume":"30","author":"Dudenbostel","year":"2017","journal-title":"Am J Hypertens"},{"key":"2022111419405462600_CIT0006","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"2022111419405462600_CIT0007","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrcardio.2013.23","article-title":"How can resistant hypertension be identified and prevented","volume":"10","author":"Solini","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"2022111419405462600_CIT0008","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2022111419405462600_CIT0009","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/ajh\/hpx210","article-title":"Spironolactone and resistant hypertension in heart failure with preserved ejection fraction","volume":"31","author":"Rossignol","year":"2017","journal-title":"Am J Hypertens"},{"key":"2022111419405462600_CIT0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1524-6175.2007.06367.x","article-title":"Aldosterone and the vasculature: mechanisms mediating resistant hypertension","volume":"9","author":"Duprez","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2022111419405462600_CIT0011","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-042711-135929","article-title":"Hyperaldosteronism as a common cause of resistant hypertension","volume":"64","author":"Calhoun","year":"2013","journal-title":"Annu Rev Med"},{"key":"2022111419405462600_CIT0012","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/2047487316675194","article-title":"Comparative effectiveness of fourth-line anti-hypertensive agents in resistant hypertension: a systematic review and meta-analysis","volume":"24","author":"Sinnott","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"2022111419405462600_CIT0013","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/jhh.2014.83","article-title":"Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy","volume":"29","author":"Gupta","year":"2015","journal-title":"J Hum Hypertens"},{"key":"2022111419405462600_CIT0014","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.12688\/f1000research.11887.1","article-title":"Spironolactone in cardiovascular disease: an expanding universe","volume":"6","author":"Funder","year":"2017","journal-title":"F1000Res"},{"key":"2022111419405462600_CIT0015","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1001\/jamacardio.2016.1878","article-title":"Mineralocorticoid receptor antagonists in the management of heart failure and resistant hypertension: a review","volume":"1","author":"Flatt","year":"2016","journal-title":"JAMA Cardiol"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/31\/4\/405\/47041487\/ajh_31_4_405.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/31\/4\/405\/47041487\/ajh_31_4_405.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T19:41:10Z","timestamp":1668454870000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/31\/4\/405\/4797112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,10]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,1,10]]},"published-print":{"date-parts":[[2018,3,10]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpy003","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,4]]},"published":{"date-parts":[[2018,1,10]]}}}